OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 20:50 UTC. Every row links to its source record.

EWSR1 EWS RNA binding protein 1

ENSG00000182944 · protein coding · Open Targets profile

Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Might normally function as a transcriptional repressor (PubMed:10767297). EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. .

In 15 of 15 cancers, the evidence for EWSR1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Ewing sarcomaEwing sarcomaEwing sarcoma: somatic 0.18Ewing sarcoma: germline 0.01desmoplastic small round cell tumordesmoplastic small round cell tumordesmoplastic small round cell tumor: somatic 0.61clear cell sarcomaclear cell sarcomaclear cell sarcoma: somatic 0.61extraskeletal myxoid chondrosarcomaextraskeletal myxoid chondrosarcomaextraskeletal myxoid chondrosarcoma: somatic 0.61synovial sarcomasynovial sarcomasynovial sarcoma: somatic 0.61myoepithelial tumormyoepithelial tumormyoepithelial tumor: somatic 0.61rhabdomyosarcomarhabdomyosarcomarhabdomyosarcoma: somatic 0.61Ewing sarcoma/peripheral primitive neur…Ewing sarcoma/peripheral primitive neuroectodermal tumorEwing sarcoma/peripheral primitive neuroectodermal tumor: somatic 0.61liposarcomaliposarcomaliposarcoma: somatic 0.61myxoid chondrosarcomamyxoid chondrosarcomamyxoid chondrosarcoma: somatic 0.61alveolar rhabdomyosarcomaalveolar rhabdomyosarcomaalveolar rhabdomyosarcoma: somatic 0.61lipomalipomalipoma: somatic 0.61malignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumormalignant peripheral nerve sheath tumor: somatic 0.61chondrosarcomachondrosarcomachondrosarcoma: somatic 0.61leiomyosarcomaleiomyosarcomaleiomyosarcoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
Antibody
UniProt loc high conf, GO CC med conf
PROTAC
Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.15207000076770782 (upper bound 0.2377299964427948). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of EWSR1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of EWSR1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.